请使用支持JavaScript的浏览器! Microbix Biosystems品牌简介 Microbix Biosystems - 品牌库 - 生物在...-蚂蚁淘商城
新闻动态

Microbix Biosystems品牌简介 Microbix Biosystems - 品牌库 - 生物在...

  
  2025-06-22
  
microbix Biosystems

加拿大Microbix Biosystems www.microbix.com 加拿大Microbix Biosystems成立于1988年,是世界顶尖生物技术公司,其流感疫苗生产技术具有世界一流水平。提供最具性价比的传染病诊断产品,如TORCH,衣原体,流感抗原 Microbix specializes in developing proprietary biological technologies, which have lead to the development of a pipeline of products in three areas; Biotherapeutics, vaccines and non-therapeutic biologics. The Company selects products for development based on potential near term market opportunity that will provide above average returns in a high margin business. Products in Microbix pipeline generally have limited regulatory barriers or no regulatory requirement at all before reaching the market.

Microbix was founded in 1988 and created Microbix Virology (Since renamed Microbix Core Base Business) which was to commercialize, develop and manufacture infectious disease antigens for medical diagnostic tests for major multinational manufacturers. While the Company has successfully commercialized over 60 products, it was recognized early that the Company could not reach its long-term revenue and profit objectives in this area alone. However, Microbix Core Base Business is profitable and generates a positive cash flow that has been used to finance its high value product pipeline. The Company\\\'s pipeline includes large market protein drugs and a proprietary vaccine technology platform. These products are either in licensing discussions or have been licensed.

Microbix Core Base Business was the basis of the technology platform Microbix has built over the years, based on cell culture, virology, protein expression, purification and characterization, from which it develops its potential lucrative products. The Company licenses its products and proprietary technologies to large global firms with franchises in target markets. Microbix transfers licensed products to these firms in exchange for a combination of substantial royalties, upfront payments and financing for all costs to market launch. Revenue from royalties has no associated cost.

本文链接: https://www.ebiomall.cn/b843-microbix/info-1616616573.html

免责声明 本文仅代表作者个人观点,与本网无关。其创作性以及文中陈述文字和内容未经本站证实,对本文以及其中全部或者部分内容、文字的真实性、完整性、及时性本站不做任何保证或承诺,请读者仅作参考,并请自行核实相关内容。
版权声明 未经蚂蚁淘授权不得转载、摘编或利用其他方式使用上述作品。已经经本网授权使用作品的,应该授权范围内使用,并注明“来源:蚂蚁淘”。违反上述声明者,本网将追究其相关法律责任。
没有了
官网分类